CD274 and non-small cell lung carcinoma: In addition, a SWOG/NRG Oncology study is investigating the addition of six months of atezolizumab (anti-PD-L1 monoclonal antibody) to SBRT in early-stage NSCLC with the primary outcome of overall survival (NCT04214262) [29].